Sanofi

Clinical Study Results Medicines, including Rare Diseases

Important

Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country. In the event that the product is described as no longer a Sanofi product, reasons could include that the product was transferred to another company.

This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.

Filter by:

And

1248 result(s) found
Generic NameTrade NameCondition(s)Study CodeStudy NameAccess to Study / ProtocolAccess to Results
BAMADUTIDE
Not marketed
Diabetes Mellitus, Type 2
PDY15264NANCT03350191Summary
BAMADUTIDE
Not marketed
Diabetes Mellitus, Type 2
TDR13700NANCT02411825Publication's Reference
BAMADUTIDE
Not marketed
Diabetes Mellitus, Type 2
TDR15516NANCT03414736Summary
BELUMOSUDIL
Rezurock
Diffuse Cutaneous Systemic Sclerosis
ACT17634/KD025-215NANCT04680975Tabulated Results
BELUMOSUDIL
Rezurock
Diffuse Cutaneous Systemic Sclerosis
EFC17665NANCT03919799Tabulated Results
BELUMOSUDIL
Rezurock
Immune system disorder
INT17676NANCT05806567Summary
BELUMOSUDIL
Rezurock
Bioavailability
KD025-106NANCT02557139Tabulated Results
BELUMOSUDIL
Rezurock
Drug-drug Interaction Autoimmune Diseases Fibrotic Disease
KD025-107NANCT03530995Tabulated Results
BELUMOSUDIL
Rezurock
Autoimmune Diseases Fibrosis
KD025-108NANCT03907540Tabulated Results
BELUMOSUDIL
Rezurock
Hepatic Impairment
KD025-109/POP17629NANCT04166942Summary

References:

* These study results were previously posted on GenzymeClinicalResearch.com
** This link replaces the same summary that was previously posted